To address these concerns, we developed a metabolically labile MEK inhibitor, NFX-179, that can be delivered topically to cNFs, providing localized and sustained inhibition of MAPK signaling in the target cNF tumor, but is rapidly metabolized in circulation to minimize systemic exposure and adverse effects. This evidence concerns the gene NPHS1 and neoplasm.